MedTrace Logo

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

NCT04820686 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2023-11-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).

Conditions

Interventions

DRUG

VBR

VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).

DRUG

AB-729

AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.

DRUG

SOC NrtI

Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.

Sponsors & Collaborators

  • Arbutus Biopharma Corporation

    collaborator INDUSTRY

  • Assembly Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-07
Primary Completion
2023-03-30
Completion
2023-03-30
FDA Drug
Yes

Countries

  • Australia
  • Bulgaria
  • Canada
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820686 on ClinicalTrials.gov